Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Hydroxychloroquine  COVID-19 treatment studies for HCQ  C19 studies: HCQ  HCQ   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 95% Improvement Relative Risk c19hcq.org Yegerov et al. HCQ for COVID-19 LATE TREATMENT Is late treatment with HCQ beneficial for COVID-19? Retrospective 1,072 patients in Kazakhstan Study underpowered to detect differences Yegerov et al., medRxiv, doi:10.1101/2021.01.06.20249091 Favors HCQ Favors control
Epidemiological and Clinical Characteristics, and Virologic Features of COVID-19 Patients in Kazakhstan: a Nation-Wide, Retrospective, Cohort Study
Yegerov et al., medRxiv, doi:10.1101/2021.01.06.20249091 (Preprint)
Yegerov et al., Epidemiological and Clinical Characteristics, and Virologic Features of COVID-19 Patients in Kazakhstan: a.., medRxiv, doi:10.1101/2021.01.06.20249091 (Preprint)
Jan 2021   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 1,072 hospitalized patients in Kazakhstan showing no mortality for HCQ treated patients, however only 23 patients received treatment - this result is not statistically significant. This study is excluded in the after exclusion results of meta analysis: unadjusted results with no group details.
risk of death, 95.3% lower, RR 0.05, p = 1.00, treatment 0 of 23 (0.0%), control 20 of 1,049 (1.9%), NNT 52, relative risk is not 0 because of continuity correction due to zero events (with reciprocal of the contrasting arm).
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Yegerov et al., 8 Jan 2021, retrospective, Kazakhstan, preprint, 8 authors, average treatment delay 1.0 days.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperHCQAll
Abstract: medRxiv preprint doi: https://doi.org/10.1101/2021.01.06.20249091; this version posted January 8, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Yegorov S et al. COVID-19 in Kazakhstan 1 Epidemiological and Clinical Characteristics, and Virologic Features of COVID-19 2 Patients in Kazakhstan: a Nation-Wide, Retrospective, Cohort Study. 3 Sergey Yegorov, PhD1*^, Maiya Goremykina, MD2^, Raifa Ivanova, MD2^, Sara V. 4 Good3, PhD, Dmitriy Babenko, MD3^, Alexandr Shevtsov, PhD4 on behalf of the COVID- 5 19 Genomics Research Group#, Kelly S. MacDonald, MD5,6 and Yersin Zhunussov, MD7 6 on behalf of the Semey COVID-19 Epidemiology Research Group . 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 1 School of Sciences and Humanities, Nazarbayev University, 53 Kabanbay Batyr Ave, Nur-Sultan, 010000, Republic of Kazakhstan. 2 Department of Rheumatology and Non-Infectious Diseases, Semey Medical University 103 Abai street, Semey, 071400, Republic of Kazakhstan. 3 Department of Biology, University of Winnipeg, 599 Portage Avenue, Winnipeg, MB, R3B2E9, Canada. 4 National Centre for Biotechnology, 13/5 Kurgalzhynskoye road, Nur-Sultan, 010000, Republic of Kazakhstan 5 Departments of Medicine, Microbiology & Immunology, Max Rady College of Medicine, University of Manitoba, 745 Bannatyne Avenue, Winnipeg, MB, R3E 0J9, Canada 6 JC Wilt Infectious Diseases Research Centre, Public Health Agency of Canada, 745 Logan Avenue, Winnipeg, MB, R3E3L5, Canada 7 Department of Public Health, Semey Medical University, 103 Abai street, Semey, 071400, Republic of Kazakhstan. 22 23 # The members of the COVID-19 Genomics Research Group (CGRG) collaborative group 24 are listed in the appendix pp. 8-9 25 26 The members of the Semey COVID-19 Epidemiology Research Group (SCERG) collaborative group are listed in the appendix pp. 8-9 1 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice. medRxiv preprint doi: https://doi.org/10.1101/2021.01.06.20249091; this version posted January 8, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Yegorov S et al. COVID-19 in Kazakhstan 1 * Corresponding author contact emails and phone: 2 sergey.yegorov@nu.edu.kz, yegorovsrg@gmail.com, +77770211487 3 ^ These authors contributed equally to this work 4 5 Key words: COVID-19; SARS-CoV-2; clinical characteristics; disease risk factors, 6 molecular epidemiology; Central Asia; Kazakhstan. 2 medRxiv preprint doi: https://doi.org/10.1101/2021.01.06.20249091; this version posted January 8, 2021. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission. Yegorov S et al. COVID-19 in Kazakhstan 1 ABSTRACT. 2 Background: The earliest coronavirus disease-2019 (COVID-19) cases in Central Asia 3 were announced in March 2020 by Kazakhstan. Despite the implementation of aggressive 4 measures to curb infection..
Late treatment
is less effective
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit